It's not your father's generics industry anymore. The once dominant strategy of price competition has given way to consolidation, market dominance, proprietary development programs, and world-class patent litigators.
Against this backdrop, the intuitive appeal of Barr Laboratories Inc. 's $588 million pooling-of-interest stock-swap acquisition of Duramed Pharmaceuticals Inc. [See Deal] is so clear that the temptation...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?